Marie Bleakley, Shelly Heimfeld, Keith R. Loeb, Lori A. Jones, Colette Chaney, Stuart Seropian, Ted A. Gooley, Franziska Sommermeyer, Stanley R. Riddell, Warren D. Shlomchik
Consort diagram of phase II nonrandomized clinical trial.
Number of patients assessed for eligibility and excluded or allocated to the trial, treated, followed, and analyzed. Patients with AML, ALL, or MDS could be allocated to nonmyeloablative HCT or to less intensive, non-TBI myeloablative HCT if the attending physician determined that their disease status required less intensive conditioning or if the patient had significant co-morbidities. Patients who were allocated to standard HCT with cyclophosphamide TBI conditioning, rather than the TN depletion trial, included patients who refused consent or lacked insurance coverage to participate in a clinical trial, those who were precluded from participating for logistical reasons, and those who did not meet eligibility criteria.